DNase Treatment for Dry Eyes

Safety and Efficacy Of Recombinant Human Deoxyribonuclease Eye Drops In Patients With Sjogren's and Non-Sjogren Dry Eye Disease

The purpose of this study is to evaluate the tolerability and preliminary efficacy of DNase eye drops in patients with Sjogren's and Non-Sjogren Dry Eye Disease.

Inclusion Criteria:

• Aged 18 years or older.
• Capable of giving informed consent and does provide informed consent.
• Documented Dry Eye Disease for at least 6 months.
• Schirmer I <10
• Corneal/ conjunctival (Rose Bengal) staining ≥1
• Ocular symptoms must be considered as annoying or activity limiting (OSDI ≥13; mild).
• Women must be post-menopausal ≥ 1 year, or surgically sterilized. If not, a negative urine pregnancy test is required within 14 days of receiving her first dose of test medication (placebo/ study drug) along with definite evidence of contraceptive use during the duration of the study.

Exclusion Criteria:

• Allergic to Deoxyribonuclease eye drops or any similar products, or excipients of Deoxyribonuclease eye drops 0.1%.
• Receiving or have received within 30 days any experimental systemic medication.
• Active ocular infection or ocular allergies.
• Any history of eyelid surgery or ocular surgery within the past 3 months.
• Corneal epithelial defect larger than 1 mm2 in either eye.
• The use of topical cyclosporine or corticosteroids within 2 weeks of enrollment
• Have active drug/alcohol dependence or abuse history